PriceTargets.com logo

Eyenovia - EYEN Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $2.00
  • Forecasted Upside: 2,064.50%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 4 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.09 As of 11/20/2024 01:00 AM ET
▼ -0.03 (-24.51%)

This chart shows the closing price for EYEN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Eyenovia Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for EYEN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for EYEN

Analyst Price Target is $2.00
▲ +2,064.50% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Eyenovia in the last 3 months. The average price target is $2.00, with a high forecast of $2.00 and a low forecast of $2.00. The average price target represents a 2,064.50% upside from the last price of $0.09.

This chart shows the closing price for EYEN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 4 contributing investment analysts is to hold stock in Eyenovia. This rating changed within the last month from a Strong Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/30/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/28/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/26/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/24/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/24/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/22/2024
  • 1 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/21/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/18/2024LADENBURG THALM/SH SHReiterated RatingBuy ➝ Neutral
11/18/2024HC WainwrightDowngradeBuy ➝ Neutral$12.00 ➝ $2.00
11/15/2024Brookline Capital ManagementReiterated RatingBuy ➝ Hold
11/15/2024William BlairReiterated RatingOutperform ➝ Market Perform
11/13/2024HC WainwrightReiterated RatingBuy ➝ Buy$12.00 ➝ $12.00
8/30/2024William BlairUpgradeStrong-Buy
8/13/2024HC WainwrightReiterated RatingBuy ➝ Buy$12.00 ➝ $12.00
7/24/2024HC WainwrightReiterated RatingBuy ➝ Buy$12.00 ➝ $12.00
5/16/2024HC WainwrightReiterated RatingBuy ➝ Buy$12.00
3/19/2024HC WainwrightReiterated RatingBuy ➝ Buy$12.00
3/6/2024HC WainwrightReiterated RatingBuy ➝ Buy$12.00
11/14/2023HC WainwrightReiterated RatingBuy ➝ Buy$12.00
11/1/2023William BlairReiterated RatingOutperform
10/17/2023Brookline Capital ManagementInitiated CoverageBuy$8.00
8/18/2023HC WainwrightReiterated RatingBuy ➝ Buy$12.00
8/11/2023HC WainwrightReiterated RatingBuy ➝ Buy$12.00
4/19/2023HC WainwrightReiterated RatingBuy$12.00
4/3/2023HC WainwrightReiterated RatingBuy$12.00
10/5/2022HC WainwrightInitiated CoverageBuy$12.00
10/26/2021Northland SecuritiesLower TargetOutperform$12.00 ➝ $9.00
4/1/2021HC WainwrightBoost TargetBuy$6.00 ➝ $8.00
3/1/2021Northland SecuritiesInitiated CoverageOutperform$10.00
10/23/2020HC WainwrightReiterated RatingBuy$7.00 ➝ $6.00
10/14/2020Roth CapitalLower TargetBuy$14.00 ➝ $11.00
8/13/2020HC WainwrightBoost TargetBuy$6.00 ➝ $7.00
7/19/2020LADENBURG THALM/SH SHReiterated RatingBuy ➝ Buy$19.00
7/1/2020HC WainwrightReiterated RatingBuy$6.00
5/14/2020HC WainwrightReiterated RatingBuy$6.00
3/26/2020HC WainwrightLower TargetBuy ➝ Buy$10.00 ➝ $6.00
2/3/2020OppenheimerDowngradeOutperform ➝ Market Perform
1/26/2020Roth CapitalReiterated RatingBuy
(Data available from 11/21/2019 forward)

News Sentiment Rating

0.03 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/24/2024
  • 1 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/24/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/23/2024
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/23/2024
  • 0 very positive mentions
  • 18 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/22/2024
  • 3 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/21/2024
  • 0 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/21/2024
  • 2 very positive mentions
  • 19 positive mentions
  • 5 negative mentions
  • 1 very negative mentions
Mentions as of
11/20/2024

Current Sentiment

  • 2 very positive mentions
  • 19 positive mentions
  • 5 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Eyenovia logo
Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.
Read More

Today's Range

Now: $0.09
Low: $0.08
High: $0.11

50 Day Range

MA: $0.46
Low: $0.09
High: $0.57

52 Week Range

Now: $0.09
Low: $0.08
High: $2.57

Volume

27,736,626 shs

Average Volume

1,735,867 shs

Market Capitalization

$5.92 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.75

Frequently Asked Questions

What sell-side analysts currently cover shares of Eyenovia?

The following Wall Street analysts have issued reports on Eyenovia in the last twelve months: Brookline Capital Management, HC Wainwright, LADENBURG THALM/SH SH, and William Blair.
View the latest analyst ratings for EYEN.

What is the current price target for Eyenovia?

0 Wall Street analysts have set twelve-month price targets for Eyenovia in the last year. Their average twelve-month price target is $2.00, suggesting a possible upside of 2,064.5%. HC Wainwright has the highest price target set, predicting EYEN will reach $2.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $2.00 for Eyenovia in the next year.
View the latest price targets for EYEN.

What is the current consensus analyst rating for Eyenovia?

Eyenovia currently has 4 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in EYEN, but not buy more shares or sell existing shares.
View the latest ratings for EYEN.

What other companies compete with Eyenovia?

Other companies that are similar to Eyenovia include Chemomab Therapeutics, Acurx Pharmaceuticals, Tempest Therapeutics, GlycoMimetics and Pieris Pharmaceuticals. Learn More about companies similar to Eyenovia.

How do I contact Eyenovia's investor relations team?

Eyenovia's physical mailing address is 295 MADISON AVENUE SUITE 2400, NEW YORK NY, 10017. The company's listed phone number is (917) 289-1117 and its investor relations email address is [email protected]. The official website for Eyenovia is www.eyenoviabio.com. Learn More about contacing Eyenovia investor relations.